3billion to launch rare disease drug 라이브 바카라사이트 project at BIO USA

[by Ji, Yong Jun] 라이브 바카라사이트, an AI-based rare genetic disease diagnostic company, announced on June 12 that it will participate in the 'BIO International Convention 2025 (hereinafter referred to as BIO USA),' the world's largest biopharmaceutical business event, to be held in Boston, USA.

This event marks 3billion’s first official platform for initiating discussions on global collaboration in the field of AI-based novel drug 라이브 바카라사이트. It represents a strategic move to lay an important foundation for the company’s future expansion into therapeutic 라이브 바카라사이트 based on genomic data.

BIO USA, hosted by the Biotechnology Innovation Organization (BIO), will take place from June 16 to 19 (local time) and is the largest global partnering event, attracting participation from approximately 1,800 pharmaceutical and biotechnology companies worldwide. At the event, 3billion plans to present its AI-driven platform for rare disease drug 라이브 바카라사이트, along with two new drug candidates, to global pharmaceutical firms and engage in discussions on various forms of collaboration, including co-라이브 바카라사이트 and technology transfer (L/O) opportunities.

3billion has been advancing its AI-driven novel drug 라이브 바카라사이트 platform by leveraging over 75,000 patient genomic datasets and more than 300,000 clinical symptom records accumulated through its whole-genome sequencing (WGS) and whole-exome sequencing (WES)-based rare genetic disease diagnostic services. The company is currently establishing an AI-based process for target discovery and candidate compound synthesis and is gradually conducting early-stage non-clinical validation of novel targets and drug candidates.

The company emphasizes that it has secured a distinct competitive edge in the rare disease treatment sector through its proprietary technology, which enables the analysis and application of high-quality clinical and genomic data acquired during the patient diagnostic process using AI. Through its participation in BIO USA, 3billion aims to explore opportunities for co-라이브 바카라사이트 and various forms of collaboration with global partners, ultimately establishing a foundation for leaping forward as a comprehensive global healthcare company encompassing both rare disease diagnostics and therapeutics.

“Rare disease treatment represents an area of exceptionally high unmet medical need on a global scale. Leveraging the extensive patient genomic data accumulated through our diagnostic services, we will continue to advance our AI-driven drug 라이브 바카라사이트 platform and drive innovation in the 라이브 바카라사이트 of novel drugs for rare diseases,” said Keum Chang-won, CEO of 3billion. “Through our participation in BIO USA, we aim to expand practical collaboration opportunities with global partners and generate new value in the global new drug 라이브 바카라사이트 market by capitalizing on our AI-based technological differentiation.”